Trials / Completed
CompletedNCT01684865
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 22 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Due to observational nature of the study protocol does not specify any dosing schedule for rituximab. |
Timeline
- Start date
- 2012-10-22
- Primary completion
- 2017-11-27
- Completion
- 2017-11-27
- First posted
- 2012-09-13
- Last updated
- 2017-12-29
Locations
1 site across 1 country: North Macedonia
Source: ClinicalTrials.gov record NCT01684865. Inclusion in this directory is not an endorsement.